HPV vaccine manufacturers' market share in China 2022
In 2022, over 62 million doses of human papillomavirus (HPV) vaccines were released in China. Thanks to the company's more effective 4-valent and 9-valent HPV vaccines, Merck Sharp & Dohme held almost three quarters of the market share, based on the total contract price of lots released. The Chinese pharmaceutical company Beijing Wantai was also gaining ground in the local market. HPV vaccines are highly effective in preventing cervical cancer and anal cancer.